Medtronic (MDT) Stock
Global medical device leader with diverse portfolio. Here's the price, business snapshot, and what's worth knowing about Medtronic in September 2026.
Medtronic PLC (MDT) is a leading global medical-technology company that designs, manufactures and sells a wide range of devices and therapies across cardiac, vascular, diabetes, neurological and spinal markets. Its portfolio includes pacemakers, insulin pumps, neurostimulation systems, spinal implants and surgical tools, generating a mix of implanted-device revenue and recurring consumables. With a market capitalisation of about $122.91bn, Medtronic benefits from ageing populations, steady demand for long-lived devices and an ongoing pipeline of incremental innovations. Important investor considerations include regulatory scrutiny, reimbursement and pricing pressures, competition from peers and emerging entrants, and occasional litigation. The company has historically returned cash through dividends and buybacks, but future payouts depend on cash flow and strategic priorities. This overview is general educational information only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future results.
Why It’s Moving
Medtronic is drawing attention after a guidance raise and fresh growth catalysts in heart devices and robotics.
- Q1 fiscal 2027 results beat expectations, and management lifted full-year guidance, signaling that demand is holding up better than investors expected.
- New updates in structural heart and robotics — including the Pi-Cardia investment and Cornerstone Robotics partnership — point to a broader growth pipeline beyond the core business.
- Recent conference appearances and investor-facing updates have reinforced the message that growth is broadening across devices, software, and procedures, which is helping sentiment around the stock.
Medtronic is drawing attention after a guidance raise and fresh growth catalysts in heart devices and robotics.
- Q1 fiscal 2027 results beat expectations, and management lifted full-year guidance, signaling that demand is holding up better than investors expected.
- New updates in structural heart and robotics — including the Pi-Cardia investment and Cornerstone Robotics partnership — point to a broader growth pipeline beyond the core business.
- Recent conference appearances and investor-facing updates have reinforced the message that growth is broadening across devices, software, and procedures, which is helping sentiment around the stock.
Sixth Month Growth Performance
When is the next earnings date for MEDTRONIC PLC (MDT)?
The next earnings date for MDT is expected on November 17, 2026. This report should cover fiscal Q2 2027. That timing fits Medtronic’s usual late-November reporting cadence for its second fiscal quarter.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Medtronic's stock, indicating confidence in its future price increase.
Financial Health
Medtronic is performing well with strong profits, cash flow, and revenue, indicating solid financial health.
Dividend
Medtronic's dividend yield of 3.13% provides a reasonable return for investors seeking dividends. If you invested $1000 you would be paid $31.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady implant demand
Implanted devices and related consumables can provide recurring revenue as populations age, though demand and pricing may vary across markets.
Global market reach
Sales span developed and emerging markets, offering diversification but exposing the company to currency and local reimbursement risks.
R&D-driven pipeline
Ongoing product development and approvals can drive long-term growth, although clinical outcomes and commercial uptake are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
